Interstitial Lung Disease Market Increasing number of drug approvals from regulatory bodies is a major factor driving the market growth | MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals

Key players entered into strategic partnership agreement to build new company, such partnerships are expected to drive the growth of the global interstitial lung disease market over the forecast period. For example, in February 2020, BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company, a pharmaceutical industry company announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases such as inflammatory bowel disease.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/4798

Growing focusing of key players on gaining approvals from regulatory bodies in order to expand their product portfolio, which is projected to augment the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, Boehringer Ingelheim Pharmaceuticals, Inc., a pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

Global Interstitial Lung Disease Market – Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus (COVID-19) pandemic is expected to drive the growth of the global interstitial lung disease market over the forecast period.

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 233 million cases and 4.7 million deaths due to coronavirus (COVID-19) were reported up till September 29, 2021, across the globe.

Thus, the COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Furthermore, in May 2020, government of India announced relief for daily wage workers and construction workers for an amount of US$ 13.3 per person for all states and union territories.

Key players are focused on inorganic growth strategies such as collaboration, which is expected to drive the growth of global interstitial lung disease market. For instance, in January 2015, Bristol-Myers Squibb Company, a pharmaceutical company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture, and commercialize Calibr’s preclinical compounds resulting from the collaboration.

The growing number of product approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market. For instance, in April 2020, Boehringer Ingelheim Pharmaceutical, Inc. announced that the European Commission had approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/4798

Growing number of inorganic growth strategies such as strategic collaboration by key market players is expected to drive the growth of global interstitial lung disease market. For instance, in March 2019, the Open Source Imaging Consortium (OSIC) announced that they had signed an agreement with Siemens Healthineers, a healthcare company, to achieve rapid advances to treat idiopathic pulmonary fibrosis (IPF) and other progressive interstitial lung diseases (ILDs).

Key Takeaways of the Interstitial Lung Disease Market:

• The global interstitial lung disease market is expected to exhibit a CAGR of 6.5% over the forecast period (2021-2028), due to growing number of drug launches by market key players. For instance, in October 2020, BDR Pharma, a pharmaceutical company announced the launch of 100 mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
• Growing number of prevalence of interstitial lung disease is projected to drive the growth of the global interstitial lung disease market over the forecast period. For instance, in 2017, according to report published in European Respiratory Journal, the prevalence was 30.2% for sarcoidosis, 12.1% for connective tissue diseases associated interstitial lung disease, and 8.2% for idiopathic pulmonary fibrosis in Paris, France.
• Key players operating in the global interstitial lung disease market include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla.

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Interstitial Lung Disease Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4798

Reasons to buy this Interstitial Lung Disease Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Interstitial Lung Disease market size estimation and recent advancements in the industry are explained.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Interstitial Lung Disease Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Interstitial Lung Disease Industry Impact

Chapter 2 Global Interstitial Lung Disease Competition by Types, Applications, and Top Regions and Countries
2.1 Global Interstitial Lung Disease (Volume and Value) by Type
2.3 Global Interstitial Lung Disease (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Interstitial Lung Disease Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Interstitial Lung Disease Market Analysis
Chapter 6 East Asia Interstitial Lung Disease Market Analysis
Chapter 7 Europe Interstitial Lung Disease Market Analysis
Chapter 8 South Asia Interstitial Lung Disease Market Analysis
Chapter 9 Southeast Asia Interstitial Lung Disease Market Analysis
Chapter 10 Middle East Interstitial Lung Disease Market Analysis
Chapter 11 Africa Interstitial Lung Disease Market Analysis
Chapter 12 Oceania Interstitial Lung Disease Market Analysis
Chapter 13 South America Interstitial Lung Disease Market Analysis
Chapter 14 Company Profiles and Key Figures in Interstitial Lung Disease Business
Chapter 15 Global Interstitial Lung Disease Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology